BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...

September 16, 2025 | News

Rona Therapeutics Submits RN3161 to Australian HREC as INHBE-Targeting GalNAc siRNA for Obesity

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161 to the Australian Human R...

September 16, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

September 16, 2025 | News

Single-Use Systems Are Rewiring Biopharma Manufacturing

Bioprocess, Unbottled Single-use systems (SUS) have become a transformative force in biopharmaceutical processing, offering an alternative to trad...

September 16, 2025 | Report

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

September 15, 2025 | News

Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma

Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...

September 15, 2025 | News

Mednovo Doses First Patient in Phase III Trial of Targeted Radiotherapeutic for GEP-NETs

Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodot...

September 12, 2025 | News

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

Cytiva and WhiteLab Genomics Partner to Accelerate AAV Genomic Medicine Development

Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timelin...

September 11, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

Evonik and Ethris Forge Strategic Alliance to Advance Next-Generation Lipid Nanoparticle Delivery

Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, ...

September 10, 2025 | News

Samsung Biologics Expands Presence in Japan with New Tokyo Office

Samsung Biologics has announced the opening of a new office in Tokyo, underscoring its long-term commitment to supporting Japan’s pharmaceutical and ...

September 09, 2025 | News

KBI Biopharma and Infinimmune Partner to Advance Manufacturing of Lead Human-First Antibody IFX-101

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotec...

September 09, 2025 | News

Servier Acquires Kaerus Bioscience’s KER-0193 in Deal Worth Up to $450M

Servier, an independent international pharmaceutical group governed by a foundation, announced that it has entered into a definitive agreement with Kaerus ...

September 09, 2025 | News

Stay Connected